S&P 500 Futures
(-0.03%) 5 204.75 points
Dow Jones Futures
(0.02%) 39 004 points
Nasdaq Futures
(-0.12%) 18 173 points
Oil
(-0.18%) $78.34
Gas
(-1.46%) $2.16
Gold
(-0.08%) $2 329.40
Silver
(-0.62%) $27.44
Platinum
(0.05%) $965.40
USD/EUR
(0.07%) $0.929
USD/NOK
(0.28%) $10.85
USD/GBP
(0.19%) $0.797
USD/RUB
(-0.46%) $90.93

Aktualne aktualizacje dla Ocugen Inc [OCGN]

Giełda: NASDAQ Sektor: Healthcare Branża: Biotechnology
BUY
100.00%
return 9.47%
SELL
100.00%
return -10.94%
Ostatnio aktualizowano6 geg. 2024 @ 23:00

22.56% $ 1.630

KUPNO 118762 min ago

@ $0.657

Wydano: 14 vas. 2024 @ 22:30


Zwrot: 148.29%


Poprzedni sygnał: vas. 14 - 16:30


Poprzedni sygnał: Sprzedaż


Zwrot: 6.16 %

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 23:00):
Profile picture for Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD...

Stats
Dzisiejszy wolumen 13.31M
Średni wolumen 10.02M
Kapitalizacja rynkowa 419.44M
EPS $-0.0300 ( 2024-05-03 )
Następna data zysków ( $-0.0600 ) 2024-05-14
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -6.27
ATR14 $0.00800 (0.49%)
Insider Trading
Date Person Action Amount type
2024-04-16 Qamar Huma Buy 308 465 Option (Right to Buy)
2024-03-18 Qamar Huma Sell 0 Common Stock
2023-09-15 Breininger Michael Buy 0
2024-01-03 Musunuri Shankar Sell 180 204 Common Stock
2024-01-03 Upadhyay Arun Sell 41 633 Common Stock
INSIDER POWER
65.41
Last 96 transactions
Buy: 10 862 012 | Sell: 2 992 475

Wolumen Korelacja

Długi: 0.27 (neutral)
Krótki: 0.95 (very strong)
Signal:(66.191) Expect same movement, but be aware

Ocugen Inc Korelacja

10 Najbardziej pozytywne korelacje
EQRR0.944
PVAL0.943
RNA0.942
THRN0.938
RAIL0.936
DVLU0.935
PCAR0.934
SG0.934
SHLD0.933
LFMDP0.932
10 Najbardziej negatywne korelacje
RMRM-0.938
RGC-0.934
UONEK-0.926
TCPC-0.922
VORB-0.921
TSP-0.919
BRQS-0.918
HCDIP-0.916
AGRX-0.91
QNRX-0.909

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ocugen Inc Korelacja - Waluta/Towar

The country flag 0.38
( neutral )
The country flag 0.39
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.36
( neutral )

Ocugen Inc Finanse

Annual 2023
Przychody: $6.04M
Zysk brutto: $5.33M (88.34 %)
EPS: $-0.260
FY 2023
Przychody: $6.04M
Zysk brutto: $5.33M (88.34 %)
EPS: $-0.260
FY 2022
Przychody: $0
Zysk brutto: $-1.07M (0.00 %)
EPS: $-0.360
FY 2021
Przychody: $0.00
Zysk brutto: $0.00 (0.00 %)
EPS: $-0.300

Financial Reports:

No articles found.

Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej